For the NO

Abstract

The addition of metformin in adults with type 1 diabetes caused small reductions in body weight and lipid levels but did not improve HbA1c. The trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide, showing modest HbA1c reductions (0.3 - 0.4%), decreases in weight ( 5 kg), and reductions in insulin doses (10 – 12%). The most frequent AEs with liraglutide were nausea and vomiting. The rate of symptomatic hypoglycemic episodes was increased with liraglutide 1.8 mg and 1.2 mg versus placebo. The rate of hyperglycemic episodes accompanied by ketosiswas increased with liraglutide 1.8 mg.

Keywords

• diabetes mellitus
• insulina